A few ra medicine products I can recommend:
Start Up – Beginners Guide To Natural Fat Loss 
Start Up - Beginners Guide To Natural Fat Loss
Monday, March 16, 2015
Start Up - Beginners Guide To Natural Fat Loss
Start Up - Beginners Guide To Natural Fat Loss
Saturday, March 14, 2015
Vesselon Announces Jon Serbousek to Serve as Chairman of the Board of Directors
Vesselon, Inc., a preclinical stage therapeutics company today announced that Jon Serbousek was named Chairman of the Board of Directors, effective February 9, 2015.
“Jon’s extensive experience in globally commercializing new medical technologies during his tenure at major medical device companies, such as Biomet, Medtronic and DePuy, will be extremely important to us as we progress. We are pleased to have him join us on our mission to save the lives and quality of life of stroke victims around the world,” stated Clayton Larsen, Co-Founder, President and CEO of Vesselon.
Mr. Serbousek is currently Worldwide President of Biomet Biologics and Sr. Vice President of Biomet, Inc., a worldwide innovator in the design and manufacture of products for the orthopedic, sports medicine, biologic, spine, cranio-maxillofacial and dental markets. Biomet Biologics, LLC is an internally ventured medical technology company, offering solutions to repair and regenerate damaged or degenerated hard and soft tissues. He has also held the positions of Group President of Orthopedics and President of US Orthopedics at Biomet.
Prior to Biomet, Jon held various general management positions with Medtronic, most recently as Worldwide Vice President and General Manager, Biologics for Medtronic’s Spinal and Biologics business. He also served in the role of Vice President and General Manager, Biologics, New Technology Development and Asia Pacific–Emerging Markets (APEC) while incubating disruptive Orthopedic and Interventional Spine start-up businesses. He had also served as Division President for a number of Medtronic business units and divisions. Before joining Medtronic, Serbousek served as Vice President of Marketing and Product Development for DePuy Orthopedics, a Johnson and Johnson company.
Mr. Serbousek earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland. Mr. Serbousek has held numerous board positions for profit and not-for-profit organizations and is currently active with OrthoWorx (Chairman), BioCrossroads, BioCrossroads Executive Committee, and Indiana BioSciences Research Institute Boards. Additionally, he is a member of the University of Memphis’ Herff School of Engineering Advisory Council and Grace College Campaign Steering Committee.
“Vesselon’s noninvasive prehospital approach and technology have the potential to significantly benefit the lives of those afflicted with acute onset stroke,” commented Mr. Serbousek. “I look forward to being a part of the team that makes this breakthrough treatment a commercial reality.”
About Vesselon
Vesselon, Inc., a Spencer Trask venture, is a preclinical stage medical device company seeking to transform ischemic stroke treatment. We are developing a new immediate treatment platform that will use non-imaging ultrasound and a contrast agent of microbubbles to dissolve clots. Just as the introduction of the AED enabled first responders to save cardiac arrest victims’ lives, we believe our device could reduce treatment time from hours to minutes and have the potential to save the lives of and quality of life for ischemic stroke victims.
About Spencer Trask Ventures
For more than 20 years, Spencer Trask Ventures, Inc. has united investors and entrepreneurs to build valuable companies that better the world. Our clients have invested more than $ 1 billion in start-up companies that went on to make significant advances in healthcare, technology and life sciences.
Related Indiana University School Of Medicine Press Releases
Vesselon Announces Jon Serbousek to Serve as Chairman of the Board of Directors
Thursday, March 12, 2015
Insilico Medicine utilizing high-performance computing to combat aging and age-related diseases selected for NVIDIA GTC Contest Finals
San Jose, CA (PRWEB) March 12, 2015
While deep learning will be the topic of many conversation at next week’s 2015 GPU technology conference, one startup will talk passionately about using high-performance NVIDIA GPU technology to fight cancer, age-related diseases and aging itself.
Insilico Medicine, a bioinformatics company located at the campus of Johns Hopkins University in Baltimore, Maryland, is one of 12 most promising technology companies selected out of the initial pool of over 150 contestants to compete in the finals of high-tech company competition at one of the though-after events in Silicon Valley, NVIDIA GPU Technology Conference.
Insilico Medicine will be exhibiting at the conference from 17th to 20th of March and will present its technology to a broad audience and a panel of high-profile judges on March 18th.
“We live in a very exciting time when information technology is converging with biotechnology blurring the boundaries, lowering barriers to entry for smaller players and creating opportunities for data wizards and machine learning experts to make a real tangible difference in human health. Insilico Medicine developed a bioinformatics platform and strategy to tackle humanity’s greatest challenge – aging and age-related diseases and we are thankful to NVIDIA for this opportunity to present our vision to some of the world’s brightest minds in tech”, said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. “NVIDIA managed to reinvent itself many times over the past two decades by acquiring crème de la crème of the most ambitious and visionary IT elite and this conference is one of their tools for attracting top talent. I would like to invite some of these geniuses to join our quest to make aging obsolete”, he added.
In just over one year Insilico Medicine scientists published over 17 papers in peer-reviewed academic journals, partnered with pharmaceutical companies and received the prestigious PMWC Palo Alto 2015 “Most Promising Company” award. The Science Advisory Board of Insilico Medicine, Inc is comprised of some of the world’s top scientists including the 2013 Nobel Laureate, Dr. Michael Levitt, director of pediatric oncology at Johns Hopkins, Dr. Donald Small, professor of NYU, Dr. Bud Mishra, head of aging and longevity lab at MIPT, Dr. Alexey Moskalev, bioinformatics of aging and longevity researcher from Stanford Dr. Kristen Fortney, co-founder of GeneGo, Dr. Yuri Nikolsky and is chaired by the ex-principal scientist of the Human Genome Project, Dr. Charles Cantor.
“NVIDIA already enabled video games to reach the level of realism and attractiveness that comes close to and even surpasses nature. But we are unlocking the power of NVIDIA GPU to create virtual cells, tissues, bodies and even virtual populations to simulate and test the effects of hundreds of thousands of compounds and therapies and reprogram human bodies to live longer and free of disease”, said Qingsong Zhu, PhD, COO of Insilico Medicine, Inc.
Insilico Medicine booth #312 can be found on the main floor of the NVIDIA GTC exhibition. Conference video is available at http://goo.gl/u3J0CF and conference soundtrack is available at http://goo.gl/QqkJXT .
About Insilico Medicine, Inc
Insilico Medicine, Inc. is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related diseases. The company utilizes the GeroScope(TM), OncoFinder(TM) , Pathway Cloud Intelligence(TM) and PharmAtlas(TM) packages for aging and cancer research, pursues internal drug discovery programs, and provides services to pharmaceutical companies. For more information on Insilico Medicine’s use of NVIDIA GPU Technology, please visit: http://goo.gl/u3J0CF for conference soundtrack, please visit http://goo.gl/QqkJXT .
Insilico Medicine utilizing high-performance computing to combat aging and age-related diseases selected for NVIDIA GTC Contest Finals
Tuesday, March 10, 2015
Dr. C. E. Gant Alternative Health Membership - Recurring
Dr. C. E. Gant Alternative Health Membership – Recurring 
Dr. C. E. Gant Alternative Health Membership - Recurring
Sunday, March 8, 2015
Drivers Should Also Buy Auto Insurance For A Stored Car
Compare-autoinsurance.org has released a new blog post explaining that even stored cars need auto insurance coverage.
Drivers who have a vehicle stored for a longer period of time should keep the auto insurance policy active. The plan can also be cancelled, if a vehicle will no longer be used for a very long period of time.
It is important to note that an auto insurance plan can also provide protection against theft and vandalism. If a stored car is stolen, an auto insurance plan can provide some financial coverage.
Clients should always review their insurance options by comparing car insurance quotes on an insurance brokerage website like: http://compare-autoinsurance.org/. An website like this provides information about the newest insurance plans available on the market.
Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.
Compare-autoinsurance.org is owned by Internet Marketing Company.
For more information, please visit http://compare-autoinsurance.org/.
More Health Insurance Press Releases
Drivers Should Also Buy Auto Insurance For A Stored Car
Saturday, March 7, 2015
Workplace Lifestyle Intervention Program Improves Health, Reduces Diabetes and Heart Disease Risks
A healthy lifestyle intervention program administered at the workplace and developed by the University of Pittsburgh Graduate School of Public Health significantly reduces risk factors for diabetes and heart disease, according to a study reported in the March issue of the Journal of Occupational and Environmental Medicine.
The program was well-received by participants at Bayer Corp., who lost weight and increased the amount of physical activity they got each day, when compared with a control group in the study, which was funded by the National Institutes of Health.
“Health care expenditures associated with diabetes are spiraling, causing widespread concern, particularly for employers who worry about employee health and productivity,” said lead author M. Kaye Kramer, Dr.P.H., assistant professor in Pitt Public Health’s Department of Epidemiology and director of the school’s Diabetes Prevention Support Center. “This leads to an interest in workplace health promotion; however, there are very few evidence-based programs that actually demonstrate improvement in employee health. This study found that our program not only improves health, but also that employees really like it.”
This demonstration program is based on the U.S. Diabetes Prevention Program (DPP), a national study that found people at risk for diabetes who lost a modest amount of weight through diet and exercise sharply reduced their chances of developing diabetes, outperforming people who took a diabetes drug instead.
Dr. Kramer and colleagues built on the DPP to create a group-based program that puts the findings into practice, called Group Lifestyle Balance™. The program is divided into 22 sessions over a one-year period and aimed at helping people make lifestyle changes to improve health. The sessions can be done as a group with a lifestyle coach or through a DVD coupled with brief weekly phone or, in certain cases, email consultations with the lifestyle coach. The option of the DVD with lifestyle coach support not only served as the main intervention option for those employees who traveled or who did not want to participate in the program in a group venue but also offered a valuable replacement for employees who chose to participate via group setting but had to miss an occasional session.
“Our Group Lifestyle Balance program has proven successful in diverse community settings, so we adapted it for the workplace since we found that there was a real need for effective programs that could fit into people’s work lives,” said senior author Andrea Kriska, Ph.D., professor in Pitt Public Health’s Department of Epidemiology and principal investigator of the study. “This current effort in the worksite shows clearly that a proven healthy lifestyle program, like the Group Lifestyle Balance program, offered to people where they work is not only feasible but effective in reducing risk factors for diabetes and heart disease for participating employees.”
A total of 89 employees at Bayer Corp. in Robinson Township, Pa., who were at risk for diabetes or heart disease were enrolled in the demonstration program in the fall of 2010 and followed for 18 months.
Over the course of a year, participants lost an average of 5 percent of their body weight (10 pounds), shrunk their waistlines by about 2 inches and brought down the levels of fat and sugar in their blood – all measures that reduce the risk of heart disease and diabetes. They also increased their physical activity by almost twofold.
Of the participants, 96 percent said they felt it was beneficial to offer the program at the worksite, and 99 percent said they would recommend it to their co-workers.
“The positive results that employees experienced from this lifestyle program speak to the benefits of personalized health programs in the workplace,” said Phil Franklin, M.D., U.S. corporate medical director, Bayer Corp. “I would like to congratulate the University of Pittsburgh researchers on the study.”
Additional authors on this research are Donald Molenaar, M.D., Veterans Health Administration in Minneapolis; Elizabeth Venditti, Ph.D., Western Psychiatric Institute and Clinic of UPMC; and Vincent C. Arena, Ph.D., Rebecca Meehan, M.S., R.D., L.D.N., Rachel Miller, M.S., Karl Vanderwood, Ph.D., and Yvonne Eaglehouse, M.S., M.P.H., all of Pitt Public Health.
This research was funded by the National Institutes of Diabetes and Digestive and Kidney Diseases (R18 DK081323–04).
About the University of Pittsburgh Graduate School of Public Health
The University of Pittsburgh Graduate School of Public Health, founded in 1948 and now one of the top-ranked schools of public health in the United States, conducts research on public health and medical care that improves the lives of millions of people around the world. Pitt Public Health is a leader in devising new methods to prevent and treat cardiovascular diseases, HIV/AIDS, cancer and other important public health problems. For more information about Pitt Public Health, visit the school’s Web site at http://www.publichealth.pitt.edu.
Workplace Lifestyle Intervention Program Improves Health, Reduces Diabetes and Heart Disease Risks
Sunday, March 1, 2015
New ACL Preservation at G2 Orthopedics and Sports Medicine
ACL tears are a common knee injury that can cause pain and instability, with over 200,000 cases annually in the United States. Orthopedic surgeon and knee and shoulder specialist Dr. Vic Goradia, is providing evolutionary treatments for patients at G2 Orthopedics and Sports Medicine with a new, less invasive tissue sparing ACL Preservation procedure – and OrthoBiologics are often a key component used to further improve the healing process.
For the past 30 years, surgeons have been treating ACL tears with what is known as an ACL reconstruction. During an ACL reconstruction, the surgeon completely removes the damaged ACL tissue from the knee, drills tunnels through the bone and inserts a graft. But with ACL Preservation surgery, if the ACL tears away from the bone, it is re-attached arthroscopically and injected with either PRP or Stem Cells- both of which come from the patient. ACL Preservation allows you to “preserve” your ACL tissue with a goal of faster recovery times, less pain, and ultimately providing a more natural feeling in your knee.
Less invasive orthopedic treatments, a focus on preservation, and the adoption of OrthoBiologics in the healing process is changing how orthopedics are delivered, and it parallels the evolution of Dr. Goradia’s own practice.
Orthobiologics support or enhance the body’s own natural ability to heal itself and can play an important role in treating acl, rotator cuff, meniscal, and cartilage injuries along with a variety of other common orthopedic conditions (arthritis, sprains, strains, tendonitis and inflammation) with outcomes that provide a continued quality of life. When surgery is needed, the evolution of arthroscopic techniques, modern imaging and the technical precision of modern surgical techniques have dramatically improved outcomes in orthopedics.
According to Dr. Goradia, “OrthoBiologics is likely to be the greatest orthopedic advancement in the 21st century, as it will allow us to promote and stimulate the body to heal itself – sometimes without surgery. The research in this field is very active and what we are doing today will change over time. This is why it is so important for me as a clinician to stay involved in the field on both a regional and national level where I have access to the latest information.”
Two examples of the importance of staying current are ACL Preservation Surgery and Biocartilage, which were hardly known just 1-2 years ago. Today, Dr. Goradia is able to perform a much less invasive procedure for many acl tears and a more effective procedure for cartilage loss.
Continued advancements in the integration of OrthoBiologics with traditional procedures suggest an exciting future for the treatment abilities of orthopedic medicine and surgery.
Dr. Vipool K. “Vic” Goradia is certified by the American Board of Orthopedic Surgery with a Certificate of Added Qualifications (CAQ) in Sports Medicine. He specializes in sports medicine, arthroscopic surgery and joint replacement. Dr. Goradia has given over 100 national presentations, regularly teaches advanced arthroscopic and related surgeries to other surgeons across the U.S. and beyond and has received several national awards for his research.
More Virginia Board Of Medicine Press Releases
New ACL Preservation at G2 Orthopedics and Sports Medicine
Subscribe to:
Posts (Atom)
